A single dose of high-dose rate brachytherapy prevents biochemical recurrence for at least 3 years in patients with low-risk prostate cancer, but is less effective among those with higher-risk disease, researchers report.
This roundup of research presented at ESTRO 37 – the annual meeting of the European Society for Radiotherapy & Oncology, held in Barcelona, Spain – covers chemoradiotherapy in older non-small-cell lung cancer patients, predictors of mortality in radiotherapy-treated NSCLC patients, and ultra-hypofractionated radiotherapy for prostate cancer.
F-sodium fluoride positron emission tomography–computed tomography allows physicians to visualize high-risk or ruptured coronary atherosclerotic plaques in patients with myocardial infarction or stable angina, research shows.
Intensity-modulated radiotherapy is equivalent to conventional conformal radiotherapy in terms of morbidity and cancer control outcomes in the treatment of prostate cancer after radical prostatectomy, shows a study published in JAMA Internal Medicine.
Radiotherapy can significantly improve the quality of life of elderly individuals with cancer that has metastasized to the bone, show study results presented at the 2nd European Society for Radiotherapy and Oncology Forum in Geneva, Switzerland.